CHEK1 and small cell lung carcinoma: For example, the IL-15 super-agonist, N-808 (43), arginine deprivation (44), and inhibition of Aurora kinase B (45), checkpoint kinase 1 (CHK1; ref. 46) have all demonstrated anticancer activity in SMARCA4-deficient SCLC-Y cell lines.